Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMX-001 with WBRT for Multiple Brain Metastases
NCT03608020Phase 2Terminated
- Sponsor
- BioMimetix
- Start
- Oct 2018
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of manganese butoxyethyl pyridyl porphyrin in brain metastases (2 arms), sponsored by BioMimetix. Primary endpoints: Proportion of patients who experience grade 4 or 5 study drug related adverse events at 1 year and Cumulative score of HVLT-R, TMT A&B and COWA at 1 year. Started Oct 2018; status: terminated.
02
Drugs
manganese butoxyethyl pyridyl porphyrin
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT03608020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03608020.